** Sarepta Therapeutics SRPT.O said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S.-approved gene therapy for Duchenne muscular dystrophy.
DOCTORS COULD BECOME MORE CAUTIOUS
** Jefferies ("buy"; PT: $165) says the therapy Elevidys could perhaps receive a blackbox warning for fatal acute liver-failure as a precautionary measure
** Brokerage adds if the death becomes attributed to SRPT's therapy, adoption could become more skewed towards patients who can walk and a strong trend of use by patients who cannot would reassure the Street about safety fears
** H.C. Wainwright ("sell"; PT: $75) says since the liver failure and death occurred in an older patient who could not walk, doctors could become even more cautious on dosing these patients
** William Blair ("outperform") says the recent infection in patient could have exacerbated the condition, suggesting additional safety screening measures could be implemented in the future to prevent future deaths
** BMO Capital Markets ("outperform"; PT: $200) says while this unfortunately negatively impacts Elevidys' overall safety profile, the benefit/risk profile is acceptable given unmet need in the DMD space
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。